We not only validated the efficacy of the identified BCL6 inhibitor WK369 as a monotherapy for ovarian cancer, but also provided a potential therapeutic option for the use of targeted agents in adjuvant chemotherapy. The gene discussed is BCL6; the disease is ovarian cancer.